Evidence map›Paper›PMID 20981323›Full record

ArticleHuman genomics and proteomics : HGP2009

Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival and Migration.

Daruka Mahadevan, James Choi, Laurence Cooke, Bram Simons, Christopher Riley, Thomas Klinkhammer, Rohit Sud, Sirisha Maddipoti, Sean Hehn, Harinder Garewal and 1 more

Open access · greenAbstract read
In one paragraph

Article in Human genomics and proteomics : HGP, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Review
  3. Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. BRAFBlood advances · 2017
    Article
  11. Review
  12. Article
  13. Review
  14. Prediagnostic transcriptomic markers of Chronic lymphocytic leukemia reveal perturbations 10 years before diagnosis.Annals of oncology : official journal of the European Society for Medical Oncology · 2014
    Article
  15. Targeting inflammatory pathways in chronic lymphocytic leukemia.Critical reviews in oncology/hematology · 2013
    Review
  16. Cell Trafficking in Chronic Lymphocytic Leukemia.Open journal of hematology · 2012
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Daruka MahadevanDepartment of Hematology/Oncology, Arizona Cancer Center, Tucson, AZ 85724, USA.
James Choi
Laurence Cooke
Bram Simons
Christopher Riley
Thomas Klinkhammer
Rohit Sud
Sirisha Maddipoti
Sean Hehn
Harinder Garewal
Catherine Spier
Arizona Oncology · USUniversity of Arizona · USHematology Oncology Associates · USRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene expression profiling (GEP) of 8 stage 0/I untreated Chronic Lymphocytic Leukemia (CLL) patients showed over-expression of Frizzled 3 (FZD3)/ROR-1 receptor tyrosine kinase (RTK), FLT-3 RTK and CXCR3 G-protein coupled receptor (GPCR). RT-PCR of 24 genes in 21 patients of the WNT pathway corroborated the GEP. Transforming growth factorβ, fibromodulin, TGFβRIII and SMAD2 are also over-expressed by GEP. Serum cytokine profiling of 26 low stage patients showed elevation of IFNγ, CSF3, Flt-3L and insulin-like growth factor binding protein 4. In order to ascertain why CLL cells grow poorly in culture, a GEP of 4 CLL patients cells at 0 hr and 24 hr in culture demonstrated over expression of CXCL5, CCL2 and CXCL3, that may recruit immune cells for survival. Treatment with thalidomide, an immunomodulatory agent, showed elevation of CCL5 by GEP but was not cytotoxic to CLL cells. Our data suggest an interplay of several oncogenic pathways, cytokines and immune cells that promote a survival program in CLL.

Identifiers

PMID20981323
PMCPMC2958625
OpenAlexW2055127969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.